Pharma Stocks To Buy 2017 Review

: Rose nearly 700% following a lucrative licensing deal with Novartis for its antibody gevokizumab.

The year’s biggest winners were often clinical-stage companies that secured major regulatory wins or licensing deals.

: A top pick for dividends (yielding ~4.2%) and growth, with shares rising 45% in 2017 driven by Humira and its cancer drug pipeline. pharma stocks to buy 2017

: Delivered a 516% return as it dominated its niche in the metabolic disease market.

While 2017 was a banner year, several headwinds shaped investment strategies: Pharm Exec's Top 50 Companies 2017 | PharmExec : Rose nearly 700% following a lucrative licensing

: Maintained its lead in prescription sales and remained a "Strong Buy" due to its robust clinical pipeline and steady dividend.

: Gained 103% , evolving from a rare-disease specialist into a large-cap biotech giant. Blue-Chip & Dividend Leaders : Delivered a 516% return as it dominated

In , the pharmaceutical sector outperformed the broader market, with the SPDR S&P Biotech ETF (XBI) surging approximately 40% , doubling the returns of the S&P 500 . This growth was fueled by significant FDA approvals and high-value partnerships between biotech startups and industry giants. 🚀 Top Performing Pharma & Biotech (2017)